{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:35:36Z","timestamp":1793352936553,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007927","name":"The University of Oklahoma Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007927","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtha.2026.08.022","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:20:03Z","timestamp":1787959203000},"page":"3939-3942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful immune tolerance induction using efanesoctocog alfa in severe hemophilia A: a case series"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6044-6068","authenticated-orcid":false,"given":"Aqsa","family":"Ashraf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3084-2351","authenticated-orcid":false,"given":"Rebekah","family":"Kuhlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osman","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanober","family":"Nusrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.08.022_bib1","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.3324\/haematol.2022.282099","article-title":"Emicizumab: the hemophilia A game-changer","volume":"109","author":"Alcedo Andrade","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.08.022_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102693","article-title":"A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors","volume":"9","author":"Castaman","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.022_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.08.022_bib4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/ejh.14427","article-title":"Immune tolerance induction with a recombinant factor VIII Fc in haemophilia A: data from a chart review study","volume":"115","author":"Klamroth","year":"2025","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2026.08.022_bib5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.blre.2018.02.003","article-title":"Review of immune tolerance induction in hemophilia A","volume":"32","author":"Schep","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2026.08.022_bib6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2516.2008.01951.x","article-title":"Side-effects and venous access issues with immune tolerance therapy","volume":"15","author":"Carcao","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.08.022_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/20406207241300809","article-title":"Rescue immune tolerance induction with a recombinant factor Fc-fused VIII: prospective ReITIrate study of clinical, humoral and cellular immune responses","volume":"15","author":"K\u00f6nigs","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtha.2026.08.022_bib8","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3324\/haematol.2023.284498","article-title":"Efanesoctocog alfa: the renaissance of factor VIII replacement therapy","volume":"109","author":"Dargaud","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.08.022_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2022.100020","article-title":"Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis","volume":"7","author":"Oomen","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.022_bib10","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.022_bib11","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood.2022019465","article-title":"Immune tolerance induction in development","volume":"141","author":"Berntorp","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.022_bib12","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1182\/blood.2022017780","article-title":"Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study","volume":"141","author":"Malec","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.022_bib13","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jtha.2024.12.039","article-title":"Tolerance to factor VIII in the era of nonfactor therapies: immunologic perspectives and a systematic review of the literature","volume":"23","author":"van Stam","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.022_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100278","article-title":"Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes","volume":"7","author":"Levy-Mendelovich","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.022_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/hae.14524","article-title":"Emicizumab state-of-the-art update","volume":"28","author":"Mahlangu","year":"2022","journal-title":"Haemophilia"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626005477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626005477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:01:37Z","timestamp":1793350897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626005477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1538783626005477"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.022","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful immune tolerance induction using efanesoctocog alfa in severe hemophilia A: a case series","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}